bullish

Biotage

Lab Tested, Market Approved: KKR’s Biotage Bid Under the Microscope

1.1k Views24 Apr 2025 14:15
KKR’s SEK 145 cash bid for Biotage offers a 60% premium, high deal certainty, and 22% annualized return potential. Squeeze-out hinges on 84% of free float tendering. Arbitrage upside remains strong.
What is covered in the Full Insight:
  • Introduction and Offer Overview
  • Valuation and Financial Analysis
  • Strategic Rationale and Board Support
  • Regulatory and Tender Requirements
  • Conclusion and Market Implications
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 6-minute read)
Discussions
(Paid Plans Only)
chart-bar
Logo
Top 5%
Jesus Rodriguez Aguilar
European Event-Driven Analyst
Multi-AssetEvent-Driven
Price Chart(Sign Up to Access)
analytics-chart
  • Loading...
x